JAK Inhibitor denied as not FDA-approved for this use by Cigna?
Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for jak inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on JAK Inhibitor
## Why Cigna Denies JAK Inhibitors as Not FDA-Approved — and Why This Is Often Wrong
A denial citing "not FDA-approved" in the context of a JAK inhibitor usually means one of two things: (1) the specific JAK inhibitor prescribed has not been FDA-approved for the particular diagnosis on the claim, making this an off-label use denial; or (2) there has been a coding or documentation error that makes the claim appear to involve an unapproved use. Both are appealable. If the drug is in fact FDA-approved for your condition, the denial is factually incorrect and you should say so directly in your appeal.
## Why This Denial Happens
JAK inhibitors have been FDA-approved for multiple distinct indications, and each approval is indication-specific. If the diagnosis code submitted does not exactly match an approved indication, Cigna's automated system may flag the claim as outside approved use even when the clinical scenario is well within the label. Off-label use of an FDA-approved drug can also be covered when supported by authoritative compendia or established clinical guidelines — federal law and many state laws require insurers to cover compendia-supported off-label use for certain plan types.
## Your Appeal Rights
- ERISA §503: requires access to the specific criteria and clinical rationale behind the denial.
- ACA §2719 External Review: available after internal appeals are exhausted. The window is approximately four months from the final adverse decision — confirm the exact deadline on your denial notice. Expedited review is available for urgent clinical situations.
- Off-label coverage mandates: for ERISA plans and many state-regulated plans, coverage of off-label use supported by recognized compendia (such as NCCN, Micromedex, or similar) may be required. Verify which compendia Cigna's policy references.
## Concrete Appeal Process
1. Verify the exact FDA-approved indications for the specific JAK inhibitor by reviewing the current FDA-approved prescribing information (label), available at the FDA's online drug database. 2. If the use is on-label, document the mismatch between the denial and the label and cite it explicitly in your appeal. 3. If the use is off-label, gather compendia support and any applicable specialist-society guideline recommendation. 4. File the internal appeal; if denied, proceed to external review.
## Documentation to Gather
- FDA prescribing label: a copy of the current approved label showing the relevant indication.
- Diagnosis documentation: clear chart confirmation of the diagnosis matching the approved indication, using accurate ICD coding.
- Compendia support (if off-label): printout of the relevant compendia entry or guideline recommendation supporting the use.
- Prescriber letter: a detailed statement explaining the approved or compendia-supported basis for the prescription.
## Criteria-Mapping Structure
Side-by-side: the denial's stated basis on the left; the FDA label text (or compendia entry) and corresponding chart documentation on the right. If the denial rests on a factual error about approval status, state this plainly and provide the label as exhibit A.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →